The company will rely more on distribution partners in Europe for its Unyvero product line while continuing highly targeted commercialization efforts in the US.
Roche said the layoffs at its Madison, Wisconsin site will start Dec. 31 and continue through June 30, 2020.
Cooper took a $24.4 million impairment charge in the second quarter on the intangible assets it acquired in 2016 from carrier screening firm Recombine.
The company entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.
The company acquired GnuBio, which was developing a droplet-based sequencing platform, in 2014 for $39.7 million in cash and $10 million in contingent payments.
The restructuring and job cuts are expected to save the firm more than $70 million annually.
Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.
The company said that it is extending the maturity of certain obligations under the terms of the acquisition deal until March 2019.
After a 54 percent quarter over quarter rise in sales of the test, Rosetta's CEO said that the realigned strategy will take the firm to profit more quickly.
As part of the deal with an institutional investor, Interpace's royalty and milestone obligations will also be terminated.
A new study catalogues the genome and evolutionary history of the oak family, UPI reports.
Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.
A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.
In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.